news
Press release
 
April 8, 2014
Corindus Vascular Robotics to Present at Design of Medical Device Conference

Corindus co-founder will lead discussion about value of robotic stent placement during coronary intervention, April 9

Waltham, MA, April 8, 2014Corindus Vascular Robotics, a leading developer of precision vascular robotics, today announced that Tal Wenderow, Co-founder and EVP of Product & Business Development of Corindus, will present at the upcoming Design of Medical Device Conference. The conference is being held April 7-10 at The Commons Hotel & McNamara Alumni Center, on the University of Minnesota Twin Cities Campus in Minneapolis, Minn.

CorPath is the first and only FDA-cleared technology that enables precise, robotic-assisted angioplasties to open arteries and restore blood flow in patients with coronary artery disease. The system enables precisely controlled, robotic-assisted angioplasties while the physician is seated in a lead-lined interventional cockpit protected from radiation exposure. CorPath allows the cardiologist to advance stents and guidewires millimeter-by-millimeter using joysticks and touchscreen controls.

Wenderow’s presentation, titled “Robotic Stent Placement during Coronary Intervention,” will review how robotic assistance has the potential to revolutionize vascular interventions by enabling procedures to be completed with robotic precision, which may improve outcomes. The discussion aims to provide state of the art perspective from leaders in the robotic industry. This session will take place on April 9 beginning at 2:00 p.m. CST.

“As a leader in the medical robotics space, we are pleased to have the opportunity to participate in this conference and share our insight and findings that point to an increasing need for robotics during coronary intervention,” said Tal Wenderow.

CorPath was highlighted at ACC 2014, where a live case was presented for the attendees. During the case, CorPath’s robotic precision was highlighted as the operator demonstrated the ability to move the stent in one millimeter increments, placing it where he, and the case panel, felt it was optimal for patient care.

In addition to Tal Wenderow’s talk, the catheter robotics session will feature speakers from other companies in the industry as well as academics from nationally recognized institutions.

To learn more about this conference, visit Design of Medical Devices Conference site.

About Corindus Vascular Robotics, Inc.

Corindus Vascular Robotics, Inc. is a global technology leader in robotic-assisted vascular interventions. The company's CorPath System is the first FDA-cleared medical device to bring robotic precision to interventional procedures. During the procedure, the interventional cardiologist sits at a radiation-shielded workstation to advance guide catheters, stents, and guidewires with millimeter-by-millimeter precision. The workstation allows the physician greater control and the freedom from wearing heavy lead protective equipment that causes musculoskeletal injuries. With the CorPath System, Corindus Vascular Robotics brings robotic precision to interventional procedures to help optimize clinical outcomes and minimize the costs associated with complications of improper stent placement during manual procedures. Corindus stands behind its product with its unique $1,000 hospital credit "One Stent Program."

For additional information, visit www.corindus.com, and follow @CorindusInc.

Forward Looking Statements

Statements made in this release that are not statements of historical or current facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of Corindus to be materially different from historical results or from any future results or projections expressed or implied by such forward-looking statements. Accordingly, readers should not place undue reliance on any forward looking statements. In addition to statements that explicitly describe such risks and uncertainties, readers are urged to consider statements in the conditional or future tenses or that includes terms such as "believes," "belief," "expects," "estimates," "intends," "anticipates" or "plans" to be uncertain and forward-looking. Forward-looking statements may include comments as to Corindus’ beliefs and expectations as to future event

Examples of such statements include statements:

  • that the level of precision that can be attained using the CorPath GRX technology, combined with the potential for remote capabilities in the future, will both expand and improve how patients are treated;
  • that Corindus has entered a transformational period with a focus on expanding its reach to partner with hospitals to build robotic programs globally;
  • that the successful completion of these procedures at Fu Wai Hospital is the first step in Corindus' growth strategy within China; and that
  • the precise positioning enhancements to the CorPath platform that allows physicians to adjust guide catheters during PCI procedures may expand the use of the CorPath GRX System to more complex cases.

Media Contacts:

Corindus Vascular Robotics, Inc.

Kate Stanton
(508) 653-3335 ext. 200
kate.stanton@corindus.com

Investor Contact:

Lynn Pieper Lewis
(415) 937-5402
ir@corindus.com
 
close the window

Please complete the form below in order to download the content.








right
close the window

Please complete the form below in order to download the content.







close the window

Please fill out this brief form to subscribe to our email newsletter.





close the window

Please complete the form below and a member of our Clinical team will contact you.






close the window

Please complete the form below in order to download the content.







close the window